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“The Talent Is in the Choices”*Giuseppe Bruschi, MD, Federico De Marco, MD, PHDThe talent is in the choices.
—Robert De Niro (1)T he ﬁrst balloon-expandable (BE) transcath-eter aortic valve replacement (TAVR) wasﬁrst tested in 1992 by Andersen et al. (2) in
an animal model. The subsequent initial human im-
plantation of a BE equine pericardial leaﬂet stent
valve via an antegrade approach was successfully
performed by Cribier et al. (3) in 2002 in a 57-year-
old man affected by severe aortic stenosis (SAS) and
cardiogenic shock. A few years later, Grube et al. (4)
reported the ﬁrst-in-human TAVR with a self-
expanding (SE) device (4). Subsequently, both BE
and SE prostheses were successfully used in Europe,
and results were documented in observational regis-
tries (5–7). This led to the CE Mark approval for trans-
femoral replacement in 2007 for SE valve (CoreValve,
porcine pericardial tissue, long SE nitinol frame,
Medtronic Inc., Minneapolis, Minnesota), followed
in 2008 by the BE valve (Edwards SAPIEN, bovine
pericardial tissue, short stainless steel frame,
Edwards Lifesciences, Irvine, California). Soon after
commercialization, the majority of European centers
started their TAVR programs with one of these de-
vices. Consequently, in the limited number of cen-
ters using both technologies at that time, device
selection was largely on the basis of the size of the
iliofemoral arteries and the size of the native aortic
annulus.
Since then, tremendous progress of this technology
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Medical.treatment of SAS in patients considered at high risk
for surgery. It is estimated that 100,000 TAVRs have
been performed worldwide, and more than 10,000
TAVRs were performed in the United States alone
since the U.S. Food and Drug Administration approval
in 2011 (8). Differently from Europe, where >10
different TAVR devices have been approved by the
European Union, in the United States, all except a few
hundred cases have been performed using previous-
generation BE or SE TAVRs.
Even if a substantial body of data exists in rela-
tion to the clinical outcome of TAVR with both
valves, from observational clinical studies, post-
marketing device-speciﬁc national registries (9–11)
and also from controlled, randomized trials (12–14),
few head-to-head comparisons have been reported
(15,16).
The CHOICE trial (Comparison of Transcatheter
Heart Valves in High Risk Patients With Severe Aortic
Stenosis: Medtronic CoreValve vs Edwards SAPIEN
XT) (17), the ﬁrst randomized clinical trial comparing
BE and SE valves, examined 241 patients affected by
SAS and at least moderate surgical risk, underwent
transcatheter aortic valve replacement at 5 centers in
Germany. The primary endpoint of the study was
“device success,” which was a composite endpoint
comprising 4 components: successful vascular access
and deployment of the device and retrieval of the
delivery system; correct position of the device;
intended performance of the heart valve without
moderate or severe regurgitation; and only 1 valve
implanted in the correct anatomic location. The study
showed higher success rates with the BE device than
with the SE device (96% vs. 76%), primarily because
of less frequent moderate or severe aortic regurgita-
tion (4% vs. 18%) and the need for a second valve
(0.8% vs. 5.8%). The rate of new permanent pace-
maker implantation was higher with the SE device
(38% vs. 17%), and the stroke rate was nonsigniﬁ-
cantly higher with the BE system (5.8% vs. 2.6%).
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802However, no signiﬁcant between-group differences
were observed in procedural or 30-day cardiovascular
mortality (4.3% in the SE valve group and 4.1% in the
BE valve group) or in symptom improvement.SEE PAGE 791The new CHOICE trial by Abdel-Wahab et al. (18),
reported in this issue of the Journal, describes the
1-year clinical outcomes and echocardiographic ﬁnd-
ings after TAVR with BE or SE valves. All patients
were followed-up for at least 1 year; pre-speciﬁed
secondary endpoints included cardiovascular mor-
tality, stroke, repeat hospitalization for heart failure,
New York Heart Association (NYHA) functional class
improvement, a combined efﬁcacy endpoint (a com-
posite of all-cause mortality between 30 days and 1
year, failure of current therapy for aortic stenosis
requiring hospitalization for symptoms of valve-
related or cardiac decompensation, and prosthetic
valve dysfunction), and major adverse cardiovascular
and cerebrovascular events (a composite of myocar-
dial infarction, cardiac or vascular surgery, and
stroke). Aortic regurgitation (AR) was evaluated by
on-site self-reported transthoracic echocardiographic
assessment by estimating the proportion of the
circumference of the valved stent occupied by the
jet: <10% was graded as mild, 10% to 20% as moder-
ate, and >20% as severe paravalvular AR.
One of the main ﬁndings of the CHOICE trial was
that the occurrence of any degree of AR was lower
in the balloon-expandable valve group with less
frequent moderate or severe AR (4% vs. 18%), which
translated into a signiﬁcant difference in success rate
with the BE than with the SE device (96% vs. 76%).
Although that was the primary endpoint, the lack of
signiﬁcant differences between the groups
in mortality, symptom improvement, or stroke at
30 days undermined the clinical relevance of the
conclusion. However, several groups reported a cor-
relation between moderate (>2þ) paravalvular regur-
gitation and 1-year mortality (19), and the results of a
German transcatheter aortic valve interventions reg-
istry showed an increased in-hospital mortality rate
>12% in patients with grade 2/4 to 4/4 AR compared
with <8% in those with grade 1/4 or no AR (20).
In the 2-year follow-up of the PARTNER trial, the
effect of AR on mortality was proportional to the
severity of the regurgitation (21). Furthermore, the
presence of AR should affect heart failure symptoms
and improvement in functional class after TAVR
(21,22).
Interestingly, from the analysis of long-term
follow-up data, between 30 days and 1 year, there
were 16 additional deaths in the BE group and 9 inthe SE group, resulting in 1-year mortality rate of
17.4% in the BE group versus 12.8% in the SE group
(p ¼ 0.37). Also, cardiovascular mortality at 1 year
was not statistically signiﬁcantly different bet-
ween BE and SE valves (12.4% vs. 9.4%), even if
11 patients in the SE group still had moderate para-
valvular regurgitation at 1 year. Symptomatic
improvement was maintained at 1 year, with no dif-
ferences between both devices, with the majority of
patients in NYHA functional class I or II, although
patients in the SE group had more hospitalizations
for heart failure.
Echocardiographic evaluation revealed no differ-
ence in the evolution of paravalvular leak over time
between the BE and SE valves, with 59.4% of patients
in whom paravalvular leak remain unchanged, and
20.3% of patients in whom paravalvular regurgitation
improved or worsened. In both groups, left ventric-
ular function slightly improved at 1 year with a sig-
niﬁcant reduction in mitral regurgitation, tricuspid
regurgitation, and pulmonary artery pressure, more
evident in the BE group. Both valves evidenced
excellent hemodynamics data at 1 year in terms of
effective oriﬁce area (>1.7 cm2) and mean gradient
(<9 mm Hg). All echocardiographic ﬁndings are
reassuring observations for TAVR.
The need for a permanent pacemaker has consis-
tently been about 3 times higher for patients treated
with the SE valve compared with the BE valve (23);
unexpectedly 7 patients, all in the BE group, required
a new pacemaker between 30 days and 1 year
compared with no patients needing new pacemakers
for the SE group.
A striking ﬁnding of the study is the relatively high
incidence of stroke, especially in the BE group (9.1%
vs. 3.4%). This ﬁnding is also in accord with the
observation of a higher number of possible valve
thromboses in the same group (3.4% vs. 0%), poten-
tially casting suspicion of an association between the
2 events, even if no patient experienced the 2 events.
The 2 devices could have different intrinsic throm-
bogenic activity, and the common pathway could
lead to different pathological expression. This state-
ment is also true when hemorrhagic strokes are not
considered.
A conclusion that can be drawn from this study is
that the clinical results are equivalent in the majority
of patients whose anatomies are suitable for treat-
ment with multiple devices. This is deﬁnitely a
reassuring observation. We are already assisting with
the proliferation of different TAVR devices on the
market because 12 different devices have been CE
Mark approved after the appearance of ﬁrst-
generation devices in 2007. What is going to be
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803very interesting in the very near future is the
administration of a “tailored TAVR therapy” in which
speciﬁc anatomic features of every single patient are
taken into account to choose the best device for his
or her speciﬁc anatomy. This is going to be the
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